U.S. Markets closed

Jounce Therapeutics, Inc. (JNCE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.21000.0000 (0.00%)
At close: 04:00PM EST
1.2700 +0.06 (+4.96%)
After hours: 07:50PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.2100
Bid1.1400 x 900
Ask1.2700 x 800
Day's Range1.1800 - 1.2700
52 Week Range0.5770 - 8.8000
Avg. Volume1,636,145
Market Cap62.55M
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-1.2400
Earnings DateFeb 28, 2023 - Mar 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
  • Zacks

    Gilead's (GILD) Application for Trodelvy Gets EMA Validation

    Gilead Sciences (GILD) gets EMA validation for its application for breast cancer drug Trodelvy in the European Union.

  • Zacks

    Gilead (GILD) To Get Full Rights for Jounce's Immunotherapy

    Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from Jounce Therapeutics.

  • Benzinga

    Gilead Sciences Acquires Jounce Therapeutics Cancer Immunotherapy Program

    Gilead Sciences Inc (NASDAQ: GILD) and Jounce Therapeutics Inc (NASDAQ: JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buyout remaining contingent payments potentially due under the license agreement executed in August 2020. GS-1811, an immunotherapy, is designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory cells in the tumor microenvironment. It is currently in Phase 1 development for solid tumors. Jounce will recei